Interaction of adenovirus with antibodies, complement, and coagulation factors

被引:31
|
作者
Allen, Rondine J. [1 ]
Byrnes, Andrew P. [1 ]
机构
[1] FDA Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, 10903 New Hampshire Ave, Silver Spring, MD 20903 USA
关键词
adenovirus; complement; natural antibody; gene therapy; immunoglobulin G; immunoglobulin M; tripartite motif-containing protein 21; vitamin K-dependent coagulation factors; FACTOR-X-BINDING; NEUTRALIZING ANTIBODIES; GENE-TRANSFER; NATURAL ANTIBODIES; VACCINE VECTORS; SERUM IGM; IN-VITRO; HEXON; IMMUNITY; VIRUS;
D O I
10.1002/1873-3468.13649
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adenovirus (AdV) is one of the most widely used vectors for gene therapy and vaccine studies due to its excellent transduction efficiency, capacity for large transgenes, and high levels of gene expression. When administered intravascularly, the fate of AdV vectors is heavily influenced by interactions with host plasma proteins. Some plasma proteins can neutralize AdV, but AdV can also specifically bind plasma proteins that protect against neutralization and preserve activity. This review summarizes the plasma proteins that interact with AdV, including antibodies, complement, and vitamin K-dependent coagulation factors. We will also review the complex interactions of these plasma proteins with each other and with cellular proteins, as well as strategies for developing better AdV vectors that evade or manipulate plasma proteins.
引用
收藏
页码:3449 / 3460
页数:12
相关论文
共 50 条
  • [1] Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement
    Zhili Xu
    Qi Qiu
    Jie Tian
    Jeffrey S Smith
    Gina M Conenello
    Takashi Morita
    Andrew P Byrnes
    Nature Medicine, 2013, 19 : 452 - 457
  • [2] Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement
    Xu, Zhili
    Qiu, Qi
    Tian, Jie
    Smith, Jeffrey S.
    Conenello, Gina M.
    Morita, Takashi
    Byrnes, Andrew P.
    NATURE MEDICINE, 2013, 19 (04) : 452 - +
  • [3] INTERACTION OF THE COMPLEMENT WITH THE SYSTEMS OF COAGULATION AND FIBRINOLYSIS
    COLOMB, MG
    BENSA, JC
    THIELENS, NM
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1983, 25 (03): : 152 - 152
  • [4] Interaction Between the Coagulation and Complement System
    Amara, Umme
    Rittirsch, Daniel
    Flierl, Michael
    Bruckner, Uwe
    Klos, Andreas
    Gebhard, Florian
    Lambris, John D.
    Huber-Lang, Markus
    CURRENT TOPICS IN COMPLEMENT II, 2008, 632 : 71 - 79
  • [5] ANTIBODIES TO BLOOD-COAGULATION FACTORS
    SHAPIRO, SS
    CLINICS IN HAEMATOLOGY, 1979, 8 (01): : 207 - 214
  • [6] Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation
    Heal, Samantha L.
    Hardy, Lewis J.
    Wilson, Clare L.
    Ali, Majid
    Ariens, Robert A. S.
    Foster, Richard
    Philippou, Helen
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (04)
  • [7] INTERACTION OF COMPLEMENT, PLATELETS, AND BLOOD-COAGULATION SYSTEM
    ZIMMERMAN, TS
    MULLEREB.HJ
    JOURNAL OF CLINICAL INVESTIGATION, 1972, 51 (06): : A107 - +
  • [8] INTERACTION BETWEEN COAGULATION AND COMPLEMENT IN MULTIORGAN SYSTEM FAILURE
    Milosevic, Danko
    Prohaszka, Zoltan
    PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2881 - 2882
  • [9] BIOLOGICAL PROPERTIES OF CHIMERIC ANTIBODIES - INTERACTION WITH COMPLEMENT
    BOULIANNE, GL
    ISENMAN, DE
    HOZUMI, N
    SHULMAN, MJ
    MOLECULAR BIOLOGY & MEDICINE, 1987, 4 (01) : 37 - 49
  • [10] INTERACTION OF COMPLEMENT AND GAMMA-GLOBULINS (ANTIBODIES)
    VALET, G
    EUROPEAN SURGICAL RESEARCH, 1982, 14 (06) : 455 - 456